

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Patient Information Leaflet (PIL).

You can also report side effects directly via the MHRA Yellow Card Scheme at <https://yellowcard.mhra.gov.uk/> or by searching for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to Pierre Fabre on 0800 0855292 or UKdrug.safety@pierre-fabre.com. By reporting side effects, you can help provide more information on the safety of this medicine.

If the neratinib dose is changed, please destroy this card and issue a new one with new dosing details.

Name:

NHS number:

Hospital number:

If you are being seen by a doctor or nurse who is not part of your usual treatment team, please show them this card.

This is a patient alert card to be carried by patients prescribed neratinib. It is intended for healthcare professionals who are not involved in the routine care of the patient. This card has been created by Pierre Fabre UK Ltd.

May 2023 Job code: UK/NER/0488

This patient is being treated with NERLYNX[®] ▼ (neratinib)

Treatment started on:

Neratinib is indicated for the extended adjuvant treatment of adult patients with early-stage hormone-receptor-positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.

Neratinib dose:

Date current dose started:

Diarrhoea is a very common and early side effect of neratinib treatment. Anti-diarrhoeal treatment should be initiated with neratinib treatment by the oncologist. Please refer to the risk minimisation materials for this product at <https://www.medicines.org.uk/emc/rmm-directory>

Consultant:

Hospital:

Nurse specialist:

**Treatment team
contact details**

Telephone:

Email:

Out-of-hours

Telephone: